Browse > Article

Recent advances in histiocytic disorders  

Seo, Jong Jin (Division of Hematology/Oncology/BMT, Department of Pediatrics, University of Ulsan College of Medicine and Asan Medical Center)
Publication Information
Clinical and Experimental Pediatrics / v.50, no.6, 2007 , pp. 524-530 More about this Journal
Abstract
The recent advances in the basic hematology and immunology have significantly enhanced the understanding of histiocytic disorders. The Histiocyte Society which was established in 1985 enabled the randomized trials for these diseases, and important knowledge regarding pathogenesis, clinical presentation, diagnosis, therapy and late consequences has been obtained. The treatment of Langerhans cell histiocytosis (LCH) has varied greatly over last decades, and is still controversial. Therapy can be reduced for low risk patients, and it is possible to discriminate early the non-responding patients with risk disease who might require more intensified treatment. Current therapy of LCH recommended by the Histiocyte Society (LCH-III protocol) is activated in 2001. Hemophaocytic histiocytosis (HLH) is fatal if diagnosis is delayed and appropriate therapy is not instituted rapidly. The diagnostic criteria for HLH is revised by the Histiocyte Society for the current treatment protocol (HLH-2004) which consists of dexamethasone, etoposide, and cyclosporin in combination with intathecal methotrexate. Hematopoietic stem cell transplantation is usually necessary for the primary HLH and recurrent secondary HLH.
Keywords
Langerhans cell histiocytosis; Hemophagocytic lymphohistiocytosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Shahlaee AH, Arceci RJ. Histiocytic disorders. In:Arceci RJ, Hann IM, Smith OP, editors. Pediatric hematology. 3rd ed. Malden:Blackwell Publishing, 2006:340-59
2 Youn HS, Song JS, Im HJ, Seo JJ, Moon HN, Ghim T, et al. The preliminary outcome of hematopoietic stem cell transplantation in patients with hemopagocytic lymphohistiocytois in Korea. Abstrat book of the 11th Congress of the Asia Pacific Bone Marrow Transplantation 2006;85
3 Imashuku S, Hibi S, Todo S, Sako M, Inoue M, Kawa K, et al. Hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan. Bone Marrow Transplant 1999;23:569-72   DOI
4 Arico M, Janka G, Fischer A, Henter J-I, Blanche S, Elinder G, et al, for the FHL Study Group of the Histiocyte Society. Hemophagocytic lymphohistiocytosis: Diagnosis, treatment and prognostic factors. Report of 122 children from the international registry. Leukemia 1996;10:197-203
5 Jabado N, de Graeff-Meeder ER, Cavazzana-Calvo M, Haddad E, Deist F, Benkerrou M, et al. Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors. Blood 1997;90:4743-8
6 Ladisch S, Gadner H. Treatment of Langerhans cell histiocytosis-evolution and current approaches. Br J Cancer 1994;70:41-6
7 Treatment Protocol of the Second International HLH Study 2004 (HLH-2004)
8 Steiner M, Matthes-Martin S, Attarbaschi A, Minkov M, Grois N, Unger E, et al. Improved outcome of treatmentresistant high-risk Langerhans cell histiocytosis after allogeneic transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005;36:215-25   DOI   ScienceOn
9 Gadner H, Grosis N, Arico M, Broadbent V, Ceci A, Jakobson A, et al. Histiocyte Society. A randomized trial of treatment for multisystem Langerhans cell histiocytosis. J Pediatr 2001;138:728-34   DOI   ScienceOn
10 Minkov M, Grois N, Braier J, Rosso D, Arico M, Broadbent V, et al for Histiocytosis Society: Immunosuppressive treatment for chemotherapy resistant multisystem Langerhans cell histiocytosis. Med Pediatr Oncol 2003;40:253-6   DOI   ScienceOn
11 Horne AC, Janka G, Egeler RM, Gadner H, Imashuku S, Ladisch S, et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Brit J Haematol 2005;129:622-30   DOI   ScienceOn
12 Janka GE. Familial hemophagocytic lymphohistiocytosis.Eur J Pediatr 1983;140:221-30   DOI
13 Donadieu J, Egeler M, Pritchard J. Langerhans cell histiocytosis: a clinical update. In:Weitsman S, Egeler R, editors. Histiocytic disorders of children and adults. 1st ed. Cambridge: Cambridge University Press, 2005:95-129
14 Baker KS, DeLaat CA, Steinbuch M, Gross TG, Loechelt B, Harris R, et al. Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. Blood 1997;89:3857-63
15 Ladisch S, Jaffe ES. Histiocytosis. In:Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. 4th edition. Lippincott Williams & Wilkins. Philadelphia. 2002;733-50
16 Sullivan KE, Delaat CA, Douglas SD, Filipovich AH. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr Res 1998;44:465-8   DOI   ScienceOn
17 Bernard F, Thomas C, Bertrand Y, Munzer M, Parker L, Ouache M, et al. Multicenter pilot study of 2-CdA and Ara-C combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005;41:2682-9   DOI   ScienceOn
18 Sullivan JL, Woda BA. Lymphohisticoytie disorders. In: Nathan DG. Orkin SH. Ginsburg DG. Look AT, editors. Nathan and Oski's Hematology of Infancy and Childhood. 6th edition. WB Saunders Co, Philadelphia. 2003;1375-95
19 Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12: 327-38   DOI
20 Henter J-I, Samuelsson-Horne AC, Arico M, Egeler RM, Elinder G, Filipovich AH, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immuno-chemotherapy and bone marrow transplantation. Blood 2002;100: 2367-2373   DOI   ScienceOn
21 Ouachee-Chardin M, Elie C, Deist F, Mahlaoui N, Picard C, Neven B, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytois; A single-center report of 48 patients. Pediatrics 2006;28:743-50